A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of Ibat Inhibition With Multidose Measurement for Evaluation of Response)
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2017
At a glance
- Drugs GSK 2330672 (Primary)
- Indications Cholestasis; Primary biliary cirrhosis
- Focus Therapeutic Use
- Acronyms GLIMMER
- Sponsors GlaxoSmithKline
- 07 Sep 2017 Planned End Date changed from 23 Apr 2018 to 9 Aug 2019.
- 07 Sep 2017 Planned primary completion date changed from 23 Apr 2018 to 9 Aug 2019.
- 20 Jan 2017 Planned End Date changed from 1 May 2018 to 1 Apr 2018.